HOME > TOP STORIES
TOP STORIES
-
BUSINESS MSD Japan Eyes Up to 8 Approvals, 8-Plus Filings under New Chief
April 10, 2026
-
REGULATORY Japan OKs Listing of Exdensur, Aquipta, Tukysa, and More; New Price Rules Applied to Two
April 9, 2026
-
BUSINESS Rising Costs Squeeze Generic Firms, Spur Calls for Unprofitable Drug Re-Pricing in 2027
April 8, 2026
-
BUSINESS BMS Files to Fully Localize Breyanzi Production in Japan
April 8, 2026
-
REGULATORY Uncertainty Clouds Start of 6-Month CEA “Technical Discussions”
April 7, 2026
-
REGULATORY Pfizer Japan Chief Urges Applying 9.6% Growth Target to Domestic Market
April 7, 2026
-
BUSINESS Drug Makers Keep New Grad Hiring Largely Flat as Sales Rep Hiring Picks Up
April 6, 2026
-
BUSINESS Japan Drug Makers Vetting Impact as Trump Unveils Tariff Details
April 6, 2026
-
REGULATORY Trump Signs Off on Up to 100% Tariffs on Drugs; Japan Rate Set at 15%
April 3, 2026
-
BUSINESS Takeda Says US Revamp “Not Simply Workforce Reduction” as 634 Roles Impacted
April 3, 2026
-
BUSINESS Human Judgment Still Key in the AI Era, Pharma Leaders Tell New Recruits
April 2, 2026
-
BUSINESS Pfizer Hails Adult Rollout of Prevenar 20 as “Milestone” for Public Health
April 1, 2026
-
ORGANIZATION JMA’s Ezawa Calls for “National Debate” on Drug Policy
March 31, 2026
-
ACADEMIA Japan Ophthalmology Society Flags Off-Label Concerns Ahead of Upneeq Launch
March 30, 2026
-
BUSINESS Otsuka to Acquire Transcend for US$700 Million, Snags PTSD Candidate
March 30, 2026
-
REGULATORY Japan Ranks 9th Among 10 in AI Analysis of EFPIA Pharma Strategy Report
March 27, 2026
-
BUSINESS Takeda Unveils Annual 200 Billion Yen Cost Savings by FY2028
March 26, 2026
-
REGULATORY Pharma Urges Govt Support as Iran War Shows Early Impact on Supply Chains
March 25, 2026
-
REGULATORY Japan OKs Bayer’s MRI Agent, Haihe’s PI3Kα Med, Enhertu’s Tumor-Agnostic Use, and More
March 24, 2026
-
BUSINESS Novo Japan Logs 5.4% Growth in 2025, Sees Wegovy Powering Push for Double-Digit Goal
March 23, 2026
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
